Ultragenyx Pharmaceutical Inc.
RARE
$35.11
-$0.87-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.46% | 29.01% | 27.44% | 19.47% | 15.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.46% | 29.01% | 27.44% | 19.47% | 15.29% |
| Cost of Revenue | 6.78% | 8.81% | 96.38% | 35.54% | 36.65% |
| Gross Profit | 12.92% | 6.05% | -314.39% | -52.95% | -58.29% |
| SG&A Expenses | 6.40% | 3.81% | 3.31% | 3.25% | 8.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.94% | 9.24% | 5.53% | -4.23% | -2.59% |
| Operating Income | 11.52% | 5.84% | 9.62% | 18.42% | 12.90% |
| Income Before Tax | 11.07% | 6.72% | 11.62% | 17.88% | 13.77% |
| Income Tax Expenses | 231.47% | 187.51% | -589.67% | -128.68% | -133.11% |
| Earnings from Continuing Operations | 10.40% | 6.17% | 12.01% | 18.82% | 14.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.40% | 6.17% | 12.01% | 18.82% | 14.70% |
| EBIT | 11.52% | 5.84% | 9.62% | 18.42% | 12.90% |
| EBITDA | 13.24% | 7.87% | 12.10% | 20.96% | 14.87% |
| EPS Basic | 26.72% | 23.93% | 28.01% | 28.85% | 21.74% |
| Normalized Basic EPS | 28.41% | 24.47% | 27.39% | 28.03% | 19.24% |
| EPS Diluted | 26.72% | 23.93% | 28.01% | 28.85% | 21.74% |
| Normalized Diluted EPS | 28.41% | 24.47% | 27.39% | 28.03% | 19.24% |
| Average Basic Shares Outstanding | 21.46% | 23.12% | 22.75% | 14.98% | 9.79% |
| Average Diluted Shares Outstanding | 21.46% | 23.12% | 22.75% | 14.98% | 9.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |